Alzforum readers who follow the science of preclinical Alzheimer's and prevention may have heard about three independent but complementary programs that together are laying the groundwork for secondary prevention trials across the spectrum of rare to common AD. Where are these projects? What have they accomplished in 2011, and what does 2012 portend? Read Gabrielle Strobel's year-end sweep of what each initiative has achieved this past year in terms of coalition building, trial planning, enrollment, and pre-trial data collection.